Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners, and alternate sites of care worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The company offers dental merchandise, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, and PPE products; dental equipment, such as dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as equipment repair; and branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, and vitamins. It also provides financial services on a nonrecourse basis, education services for practitioners, consulting, and other services; and consumable merchandise under its own brand. In addition, the company manufactures, markets, and sells dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products and other health care-related products and services. Further, it is involved in the development and distribution of practice management software, e-services, and other products to health care providers. The company serves customers in dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics and other alternate care clinics. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

Henry Schein, Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pacira Pharmaceuticals (PCRX), BioNTech SE (BNTX) an...

Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX), BioNTech SE (BNTX) and Henry Schein (HSIC)

Henry Schein (($HSIC)) has held its Q2 earnings call. Read on for the main highlights of the call. Henry Schein’s latest earnings call struck an up...

Henry Schein’s Earnings Call Highlights Growth and Guidance

In a report released today, Jason Bednar from Piper Sandler maintained a Buy rating on Henry Schein, with a price target of $95.00. According to Ti...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HSIC	$89.77	-0.39%	1.16M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HSIC	$89.77	-0.4%	1.16M
3
4
5
6

HSIC

Get Henry Schein, Inc. Data in Excel

Get Henry Schein, Inc. Data in Excel